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Abstract
Lassa virus (LASV) is a causative agent of hemorrhagic fever in West Africa. In recent
years, it has been imported several times to Europe and North America. The method of
choice for early detection of LASV in blood is RT-PCR. Therefore, the European Network
for Diagnostics of ‘Imported’ Viral Diseases (ENIVD) performed an external quality assess-
ment (EQA) study for molecular detection of LASV. A proficiency panel of 13 samples con-
taining various concentrations of inactivated LASV strains Josiah, Lib-1580/121, CSF, or
AV was prepared. Samples containing the LASV-related lymphocytic choriomeningitis virus
(LCMV) and negative sera were included as specificity controls. Twenty-four laboratories
from 17 countries (13 European, one African, one Asian, two American countries) participat-
ed in the study. Thirteen laboratories (54%) reported correct results, 4 (17%) laboratories re-
ported 1 to 2 false-negative results, and 7 (29%) laboratories reported 3 to 5 false-negative
results. This EQA study indicates that most participating laboratories have a good or accept-
able performance in molecular detection of LASV. However, several laboratories need to re-
view and improve their diagnostic procedures.
Author Summary
A proficiency test panel for molecular diagnostic of Lassa virus provides objective evidence
of testing quality of International diagnostic laboratories. Since there are no commercial
assays available, it is very important to assess the quality of diagnostic test used as well as
evaluate detection sensitivity and specificity performance. Participating laboratories have
received samples containing different inactivated Lassa virus strains as well as two negative
controls. Participants were asked to provide information on diagnostic test procedure and
protocols used for analysis of samples of Lassa virus External Quality Assessment (EQA).
Based on received information we were able to compare and evaluate the quality of diag-
nostic profile and facilitate further improvement. Participating laboratories may use re-
sults of Lassa virus EQA to become accredited for Lassa virus molecular diagnostic. Since
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different Lassa virus strains are not available for most of the laboratories, participants
achieved very advanced training for diagnostic of rare and imported viruses.
Introduction
Lassa fever was first described in 1969 as the cause of a nosocomial outbreak of hemorrhagic
fever in Nigeria [1]. Lassa fever is an acute viral infection associated with a wide spectrum of
disease manifestations, which range from mild courses to multiorgan failure [1–3]. The etio-
logic agent of Lassa fever is Lassa virus (LASV, family Arenaviridae, genus Arenavirus) [4].
The natural host of LASV is the small rodentMastomys natalensis, which lives close to human
settlements [5]. The rodents can become chronically infected at birth and excrete infectious
virus in urine and other body fluids, with subsequent transmission to humans [6]. There is ev-
idence of human-to-human transmission in both hospital and community settings [7]. The
fact that LASV may be transmitted from human to human gives rise to nosocomial or com-
munity-based outbreaks. LASV is endemic in the countries of Nigeria, Liberia, Sierra Leone,
and Guinea [8, 9] and was detected in Mali [10, 11]. Seroepidemiological studies and imported
cases of Lassa fever indicate that arenaviruses circulate somewhere in the region comprising
Côte d’Ivoire and Burkina Faso [12]. The annual incidence is estimated at 300,000 cases, with
5,000 fatalities per year [13, 14]. Additionally, LASV has been introduced several times into
Europe, Japan, and North America. Among the hemorrhagic fever viruses of risk group 4
(such as Crimean-Congo hemorrhagic fever, Ebola, and Marburg virus), LASV has been most
frequently imported [15]. The virus usually is imported by returning travelers [16, 17]. Within
Europe, LASV infections have been imported to Germany [18, 19], The Netherlands [20] and
the United Kingdom [21].
Laboratory testing is required to establish a diagnosis, as Lassa fever can hardly be distin-
guished from other febrile diseases based on clinical symptoms [14, 22]. A suspected case must
be rapidly ruled out or verified to facilitate appropriate case management, including treatment,
the implementation of isolation measures, or the tracking of contact persons [18].
The method of choice for early detection of LASV in blood is reverse transcription (RT)-
PCR [23–29]. However, the high degree of genetic variability of the virus poses a problem
with the design of RT-PCR assays for the reliable detection of all virus strains [30]. The per-
formance of the different techniques applied for molecular diagnosis of LASV may vary be-
tween laboratories. External quality assessment (EQA) studies for LASV molecular
diagnostics have not been performed since 2004 [31]. An EQA study allows the participating
laboratories to monitor the quality of their diagnostics and to identify problems with particu-
lar diagnostic assays. For these reasons, an EQA study for the molecular diagnosis of LASV
was conducted by the European Network for Diagnostics of ‘Imported’ Viral Diseases
(ENIVD) (http://www.enivd.org) in 2013. ENIVD is concerned with the development of lab-
oratory diagnostic capacities for imported virus infections, quality control, standardization of
laboratory procedures, and training of laboratory staff [32]. Based on the results of this study,
the quality of LASV diagnostics may be improved.
Materials and Methods
Call for participation
Twenty-eight laboratories involved in diagnostics of viral hemorrhagic fevers were invited to
participate in this study. Invitees were selected from the register of ENIVD network members
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and from the list of national and regional reference laboratories for rare, emerging, and danger-
ous viruses. The participation in the study was free of charge. Participants permitted publica-
tion of the results in a comparative and anonymous manner. This EQA was coordinated by
ENIVD according to the established procedures of the network [33–35].
Sample preparation
The proficiency test panel included 13 LASV preparations derived from culture supernatants
of Vero E6 cells (ATCC—American Type Culture Collection) infected with 4 different LASV
strains. Virus in cell culture supernatant was inactivated by heat (1 h at 60°C) followed by
gamma irradiation (25 kilo gray). The test panel consisted of six samples of LASV strain Josiah
from Sierra Leone, obtained by serial 10-fold dilution of cell culture supernatant (1:10 to
1:106), three samples of LASV strain Lib-1580/121 from Liberia (dilutions 1:103 to 1:105),
LASV strain CSF from Nigeria (dilution 1:103), and LASV strain AV from Cote d’Ivoire or
Burkina Faso (dilution 1:103). The samples were freeze-dried in 3% mannitol based formula-
tion using an EPSILON 2-6D Pilot Freeze Dryer (Martin Christ GmbH, Osterode am Harz,
Germany). In addition, we included one sample containing LASV strain Josiah at a dilution of
1:104 (sample #14) that was prepared with a new dry stabilizer method (Biomatrica, Inc., San
Diego, CA, USA), and one sample containing LASV strain Lib-1580/121 at dilution of 1:104
(sample #6) that was prepared using a liquid stabilizer (Biomatrica). A sample containing lym-
phocytic choriomeningitis virus (LCMV), the prototype member of the family Arenaviridae, as
well as two negative control sera were included in the test panel as specificity controls.
After lyophilized sample preparation, the samples were tested and quantified by an in-
house real-time PCR assay for quality control purpose. The assay was performed by employing
12.5 pmol of forward primer LaV F2 (CCACCATYTTRTgCATRTgCCA), 13 pmol of reverse
primer LaV R (gCACATgTNTCHTAYAgYATggAYCA) and 5 pmol of probe LaV TM
(FAM-AARTggggYCCDATgATgTgYCCWTT-BBQ). The real-time PCR assay was carried
out in one-step format on ABI 7500 real-time PCR system using the AgPath-ID One-Step
RT-PCR Kit according to manufacturer´s instruction. Plasmid standards were used for the
quantification of the genome copies of Lassa virus RNA.
Ethics statement
The EQA was performed according to National Ethical regulations.
Validation and dispatch of the panel sets
Before dispatching the panel, samples were sent to the reference laboratory for testing the qual-
ity and obtaining the reference results. Reference laboratory used RT-PCR protocol described
by Ölschläger et al., 2010 [27]. Samples were resuspended in 100 μl of water and the RNA was
extracted using the QIAamp viral RNA kit (Qiagen, Hilden, Germany). The presence of LASV
or LCMV RNA in the samples was ascertained by RT-PCR and sequencing. The number of
LASV genome copies present in these samples was determined by qRT-PCR. Samples were
shipped by regular mail at ambient temperature. Participating laboratories were instructed to
resuspend the samples in 100 μl of water and to analyze the material like serum samples poten-
tially containing LASV using their routine nucleic acid detection assays. The EQA panel was
accompanied by documentation including instructions and an evaluation form for results. Par-
ticipants were asked to report the assay protocol, the result for each sample, the LASV strain
identified, the number of genome copies as well as any problem encountered.
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Evaluation of the results
To guarantee anonymous data evaluation and reporting, each participating laboratory was
coded with an identifier. The results were scored according to detection rate and specificity as
in previous EQA studies of ENIVD [33–35]. We assigned one point for correct results; false-
negative, false-positive, and indeterminate results did not count. Results were classified as
“good”—when all results were correct; “acceptable”—when 1 to 2 results were incorrect; and
“need for improvement”—when more than 2 results were incorrect. Results for the sample con-
taining LCMV (sample #3) were not included in the score, as verification of the sequence was
optional. In addition, we excluded from scoring the sample containing LASV strain Josiah at a
dilution of 1:106 (sample #15) as this concentration is likely to be below the 95%-detection
limit of most assays. Thus, obtaining a positive or negative result becomes a matter of chance.
Each laboratory received the complete summary of the results in an anonymous way, by which
only the own laboratory was recognizable.
Results
Twenty-four (86%) of the 28 laboratories, which received the EQA material, reported results.
The 24 participating laboratories, located in 17 countries—13 European, one African, one
Asian, and two American countries (Table 1). The LASV detection rate varied among laborato-
ries and scores ranged from 9 to the maximum of 14 (Table 2). Average score for all
Table 1. List of participating laboratories.
Name of Participating laboratory City, Country
Arbovirus and Imported Viral Disease Unit, Centro Nacional de Microbiologia, Instituto de Salud Carlos III Madrid, Spain
Aristotle University of Thessaloniki, School of Medicine A, Department of Microbiology Thessaloniki, Greece
Cantacuzino Institute Vector-Borne Diseases & Medical Entomology Bucharest, Romania
Departamento de Microbiología, Hospital Clinic i Provincial de Barcelona (Barcelona, Spain); Dipartimento di Istologia,
Microbiologia e Biotecnologie Mediche, Università di Padova
Padova, Italy
DSO National Laboratories Singapore, Singapore
Erasmus MC Nb 1052, Dept. Viroscience Rotterdam, The Netherlands
Institut für Mikrobiologie der Bundeswehr, Zentralbereich Diagnostik München, Germany
Institute for Novel and Emerging Infectious Diseases, Friedrich-Loeffler-Institut); Greifswald—Insel Riems,
Germany
Institute of Microbiology and Immunology, University of Ljubljana Ljubljana, Slovenia
Laboratoire P4 Inserm Jean Mérieux Lyon, France
Laboratory of Virology, University Hospitals of Geneva Geneva, Switzerland
Laboratory of Virology, National Institute for Infectious Diseases "L Spallanzani" Rome, Italy
National Center for Epidemiology virologické odd. Budapest, Hungary
Rare & Imported Pathogens Department, Public Health England Porton Down, Salisbury, UK
Swedish Institute for Infectious disease control Stockholm, Sweden
Vector Design and Immunotherapy, National Microbiology Laboratory, Public Health Agency of Canada Winnipeg, Canada
Special Pathogens Unit, National Institute for Communicable Diseases Sandringham, South Africa
Spiez Laboratory—Virology Spiez, Switzerland
Spiez Laboratory—Federal Office for Civil Protection Spiez, Switzerland
TIB MOLBIOL Syntheselabor GmbH Berlin, Germany
Unit for Emergency Response and Biopreparedness, National Institute of Health Lisbon, Portugal
Unité de Virologie-IRBA Lyon, France
Viral Special Pathogens Branch, National Center for Emerging and Zoonotic Infectious Diseases, CDC Atlanta, U.S.A
Departamento de Microbiología Hospital Clinic i Provincial de Barcelona Barcelona, Spain
doi:10.1371/journal.pntd.0003793.t001
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participating laboratories was 13 points. Good results were achieved by 13 (54%) laboratories,
4 (17%) laboratories achieved acceptable results, and 7 (29%) laboratories had need for im-
provement. Table 3 shows that 13 (54%) laboratories correctly detected LASV in all 12 LASV
samples (100% detection rate). Three (12%) participants had one false negative result (92% de-
tection rate). Eight participants had a detection rate between 58% and 83%. None of the labora-
tories reported false-positive results for the negative control samples.
All participating laboratories were able to detect LASV strain Josiah at 1:10, 1:100, and 1:104
dilution (Table 4). Two laboratories did not detect the Josiah strain at 1:103 dilution (sample
#5) but detected the 1:104 to 1:106 dilutions of this strain (Table 2). A mix-up between sam-
ple#5 and sample #6 is a likely explanation. LASV strains AV from Cote d’Ivoire/Burkina Faso
and CSF from Nigeria were detected correctly by all laboratories. Four laboratories did not de-
tect at all the Liberian LASV strain. Further laboratories did not detect the higher dilutions of
the Liberian strain ( 1:104).
Nineteen participants used published RT-PCR protocols, two laboratories used unpublished
in-house RT-PCR assays, one laboratory used a combination of real-time and conventional
RT-PCR, and two laboratories did not provide information about the protocol. Three laborato-
ries confirmed their results by using a second published protocol. Table 5 shows that 11 (50%)
laboratories used the protocol published by Ölschläger et al., 2010 [26]. These 11 laboratories re-
ported nine false-negative results (detection rate of 93% for this protocol). Seven laboratories
using the Ölschläger et al. protocol did not report any false-negative result. Six participants
(27%) used the protocol of Vieth et al., 2007 [29] (Table 5). They reported 12 false-negative re-
sults (detection rate of 83% for this protocol). Two laboratories using this protocol did not report
any false-negative results. Three other protocols (Demby et al., 1994 [23]; Coulibaly N’Golo
Table 3. LASV detection rate by participant.
Participant number False-negative results Detection rate, %
1, 2, 4, 5, 6, 10, 14, 15, 16, 17, 18, 21, 23 0/12 100
13, 19, 20 1/12 92
12 2/12 83
7a, 7b, 22 3/12 75
3, 9, 11 4/12 67
8 5/12 58
doi:10.1371/journal.pntd.0003793.t003
Table 4. LASV detection rate by sample.
Result according to sample no., virus strain, and dilution



































0/24 0/24 2/24 0/24 1/24 3/24 11/24 0/24 0/24 4/24 7/24 6/24 8/24
Detection
rate, %
100 100 92 100 96 88 54 100 100 84 71 75 67
a with stabilizer;
b not included in score
doi:10.1371/journal.pntd.0003793.t004
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et al, 2011 [28]; Drosten et al., 2002 [27]) were used by one or two laboratories (Table 5). In the
supplementary file (S1 Fig) we are showing partial alignments of the S-segment sequences of
LASV strains used in the EQA with position of some published primers: (A) forward primer se-
quence and position on S-segment alignment; (B) reverse primer sequence and position on S-
segment alignment. In comparison to Demby et al., Lassa RT-PCR assay described by Ölschläger
et al. had just modified reverse primer in order to detect all described Lassa virus strains.
Ten laboratories (42%) reported the presence of LCMV in sample #3. In addition, 9 (37%)
laboratories reported this sample as negative, which is also considered a correct result because
this EQA was conducted to test for the ability to detect LASV. Five laboratories (21%) reported
the sample containing LCMV as positive for LASV. These laboratories used protocols for de-
tection of Old World arenaviruses, including LCMV. This underlines the relevance of sequenc-
ing the diagnostic PCR products when using pan-virus family detection assays.
Conclusions
This EQA study indicates that most participating laboratories, located in various countries
around the world, have a good or acceptable performance in molecular detection of LASV.
However, several laboratories need to improve their performance, in particular with respect to
detection of the Liberian strain. The data allow the participating laboratories to identify the
weakness in their diagnostic procedures and to review and improve their protocols.
One published protocol has achieved 100% detection rate reported by single participant.
However, the reference laboratory recommends Ölschläger et al., 2010 published protocol for
LASV detection as most commonly used with good detection rate and ability to detect all de-
scribed Lassa virus strains. The main aim of this EQA study was not to compare published pro-
tocols, rather to give chance to participating laboratories to evaluate their testing performance
and provide practical exercise for molecular detection of LASV. There should be a follow-up
EQA for molecular detection of LASV to evaluate a possible improvement.
Supporting Information
S1 Fig. Partial alignments of the S-Segment sequences of LASV strains used in the EQA
with position of some published primers.
(TIF)
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